Get started
Author

Riikka Oksala

Observed name: R. Oksala
ORCID: 0000-0001-6256-562X
Observed ORCID: 0000-0001-6256-562X
OpenAlex ID: A5082795809
Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies
2015 · Anu-Maarit Moilanen, Reetta Riikonen, et al. · Scientific Reports · 391
PDF
Castration Induces Up-Regulation of Intratumoral Androgen Biosynthesis and Androgen Receptor Expression in an Orthotopic VCaP Human Prostate Cancer Xenograft Model
2014 · Matias Knuuttila, Emrah Yatkin, et al. · American Journal Of Pathology · 65
PDF
Optimized design and analysis of preclinical intervention studies in vivo
2016 · Teemu D. Laajala, Mikael Jumppanen, et al. · Scientific Reports · 48
PDF
ODM-203, a Selective Inhibitor of FGFR and VEGFR, Shows Strong Antitumor Activity, and Induces Antitumor Immunity
2018 · Tim H. Holmström, Anu-Maarit Moilanen, et al. · Molecular Cancer Therapeutics · 34
PDF
Sexual incentive motivation in male rats requires both androgens and estrogens
2009 · Martti Attila, Riikka Oksala, et al. · Hormones and Behavior · 34
First-in-Class Small Molecule to Inhibit CYP11A1 and Steroid Hormone Biosynthesis
2022 · Mari Karimaa, Reetta Riikonen, et al. · Molecular Cancer Therapeutics · 33
Adrenals Contribute to Growth of Castration-Resistant VCaP Prostate Cancer Xenografts
2018 · Riikka Huhtaniemi, Riikka Oksala, et al. · American Journal Of Pathology · 28
PDF
ODM-201, a new generation androgen receptor inhibitor for castration-resistant prostate cancer: Preclinical and phase I data.
2013 · Karim Fizazi, Christophe Massard, et al. · Journal of Clinical Oncology · 27
Discovery and development of ODM-204: A Novel nonsteroidal compound for the treatment of castration-resistant prostate cancer by blocking the androgen receptor and inhibiting CYP17A1
2018 · Riikka Oksala, Anu Moilanen, et al. · The Journal of Steroid Biochemistry and Molecular Biology · 23
PDF
Antiandrogens Reduce Intratumoral Androgen Concentrations and Induce Androgen Receptor Expression in Castration-Resistant Prostate Cancer Xenografts
2017 · Matias Knuuttila, Arfa Mehmood, et al. · American Journal Of Pathology · 15
PDF
High intratumoral dihydrotestosterone is associated with antiandrogen resistance in VCaP prostate cancer xenografts in castrated mice
2022 · Riikka Huhtaniemi, Petra Sipilä, et al. · iScience · 13
PDF
ODM-204, a Novel Dual Inhibitor of CYP17A1 and Androgen Receptor: Early Results from Phase I Dose Escalation in Men with Castration-resistant Prostate Cancer
2018 · Katriina J. Peltola, Petri Bono, et al. · European Urology Focus · 11
SUN-LB002 CYP11A1 Inhibition as a Therapeutic Approach for the Treatment of Castration Resistant Prostate Cancer
2019 · Riikka Oksala, Mari Karimaa, et al. · Journal of the Endocrine Society · 4
CYP11A1 inhibition as a therapeutic approach for the treatment of castration resistant prostate cancer.
2018 · Riikka Oksala, Mari Karimaa, et al. · Journal of Clinical Oncology · 4
ODM-208, a novel CYP11A1-inhibitor as a therapeutic approach for the treatment of castration-resistant prostate cancer
2017 · R. Oksala, M. Karimaa, et al. · Annals of Oncology · 3
CYP11A1 inhibition as a therapeutic approach for the treatment of castration resistant prostate cancer
2018 · R. Oksala, K. Räsänen, et al. · Annals of Oncology · 1
Abstract 4968: Importance of tumor microenvironment in the preclinical estrogen receptor positive breast cancer- Primary tumor and bone metastasis models
2017 · Jenni Bernoulli, Mari I. Suominen, et al. · Cancer Research · 1
Contribution of mouse adrenal glands to intratumor androgens and growth of castration-resistant prostate cancer xenografts.
2017 · Elahe A. Mostaghel, Heather Biehl, et al. · Journal of Clinical Oncology · 1
ODM-204, a novel dual inhibitor of CYP17A1 and androgen receptor for the treatment of castration-resistant prostate cancer.
2016 · Pekka Kallio, Riikka Oksala, et al. · Journal of Clinical Oncology · 1
ODM-204: A novel dual inhibitor of CYP17A1 and androgen receptor for the treatment of castration-resistant prostate cancer—Preclinical data.
2015 · Riikka Oksala, Anu Moilanen, et al. · Journal of Clinical Oncology · 1
432 ODM-203, a novel, selective and balanced FGFR and VEGFR inhibitor with strong anti-tumor activity in FGFR- and VEGFR-dependent cancer models
2014 · T. Holmström, A. Moilanen, et al. · European Journal of Cancer · 1
4.25eP Orchidectomy-induced osteosarcopenia in aged rats: a preclinical model for muscle research
2026 · Jenni Mäki-Jouppila, Eija Aho, et al. · Neuromuscular Disorders
Supplementary Data from First-in-Class Small Molecule to Inhibit CYP11A1 and Steroid Hormone Biosynthesis
2023 · Mari Karimaa, Reetta Riikonen, et al.
Data from ODM-203, a Selective Inhibitor of FGFR and VEGFR, Shows Strong Antitumor Activity, and Induces Antitumor Immunity
2023 · Tim H. Holmström, Anu-Maarit Moilanen, et al.
Supplementary Table S1 and Figures S1-S7 from ODM-203, a Selective Inhibitor of FGFR and VEGFR, Shows Strong Antitumor Activity, and Induces Antitumor Immunity
2023 · Tim H. Holmström, Anu-Maarit Moilanen, et al.
Works count: 35
Citation count: 739
H-index: 11
I10-index: 12
Year
Topic
Type